文献速递复苏、休克与脓毒症心脑血管急症

肾上腺素剂量与时机对院外心脏骤停生存及神经功能结局的影响

Impact of adrenaline dose and timing on out-of-hospital cardiac arrest survival and neurological outcomes.
PubMed 文献 · Resuscitation · 2019-04-13
一句话结论回顾性注册数据显示,院外心脏骤停患者出院存活者首剂肾上腺素给予更早(中位5.0 vs 7.0 min)且总剂量更低(2.0 vs 3.0 mg),但首剂时间与良好神经结局无关。

该研究基于Penn Alliance for Therapeutic Hypothermia(PATH)数据注册库,回顾性分析肾上腺素给药时机与总剂量对心脏骤停患者自主循环恢复(ROSC)及神经功能的影响。最终纳入1826例院外心脏骤停、可电击心律且接受肾上腺素的患者。出院存活者首剂肾上腺素给予更早(中位5.0 vs 7.0 min,p=0.022)且总剂量更低(2.0 vs 3.0 mg,p<0.001)。在存活者中,首剂时间与脑功能分级(CPC)良好神经结局无显著关联;接受<2 mg肾上腺素者良好神经结局(CPC 1-2)比例高于>3 mg者(16.6% vs 12.5%,p=0.004)。结论提示早期给药与出院存活率提高相关,但与良好神经结局无关;神经结局良好者ROSC前总肾上腺素剂量更低。

要点

  • 出院存活者首剂肾上腺素给予更早(中位5.0 vs 7.0 min,p=0.022),且总剂量更低(2.0 vs 3.0 mg,p<0.001)。
  • 在存活者中,首剂肾上腺素时间与良好神经结局(CPC)无显著关联。
  • 存活者中接受<2 mg肾上腺素者CPC 1-2比例高于>3 mg者(16.6% vs 12.5%,p=0.004)。
  • 2015 ILCOR高级心血管生命支持指南推荐静脉肾上腺素作为心脏骤停复苏的关键药物治疗。
  • 该研究为回顾性注册数据分析,纳入1826例院外心脏骤停、可电击心律且接受肾上腺素的患者。

适用人群与场景

  • 院外心脏骤停患者,心脏骤停持续时间大于10分钟,可电击心律,并接受肾上腺素给药。
  • 排除院内心脏骤停、不可电击心律及未接受肾上腺素给药的患者。

研究设计与关键结果

  • 研究类型为回顾性分析,数据来自Penn Alliance for Therapeutic Hypothermia(PATH)注册库,共5594例患者,排除院内心脏骤停、不可电击心律或未接受肾上腺素者后,最终纳入1826例进行分析。
  • 出院存活者首剂肾上腺素给予时间早于非存活者(中位5.0 vs 7.0 min,p=0.022)。
  • 出院存活者肾上腺素总剂量低于非存活者(2.0 vs 3.0 mg,p<0.001)。
  • 在存活者中,首剂肾上腺素时间与脑功能分级(CPC)评估的良好神经结局无显著关联。
  • 存活者中,接受少于2 mg肾上腺素者良好神经结局(CPC 1-2)比例高于接受大于3 mg者(16.6% vs 12.5%,p=0.004)。

证据类型、等级与局限

  • 证据类型:回顾性注册数据分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 2015 ILCOR高级心血管生命支持指南推荐静脉肾上腺素作为心脏骤停复苏的关键药物治疗。
  • 该回顾性分析显示早期肾上腺素给药与较高的出院存活率相关,但与良好神经结局无关;神经结局良好的患者ROSC前总肾上腺素剂量更低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: The 2015 ILCOR Advanced Cardiovascular Life Support Guidelines recommend intravenous adrenaline (epinephrine) as a crucial pharmacologic treatment during cardiac arrest resuscitation. Some recent observational studies and clinical trials have questioned the efficacy of its use and suggested possible deleterious effects on overall survival and long-term outcomes. This study aimed to describe the association between time and dose of adrenaline on return of spontaneous circulation (ROSC) and neurologic function.

METHODS: We performed a retrospective analysis of the Penn Alliance for Therapeutic Hypothermia (PATH) data registry. The timing of the first dose of adrenaline and the total dose of adrenaline during cardiac arrests was compared between survivors to discharge and non-survivors for arrests lasting greater than 10 min.

RESULTS: The registry contained 5594 patients. After excluding patients with an in-hospital cardiac arrest, a non-shockable rhythm, or no adrenaline administration, 1826 were included in the final analysis. Survivors to discharge received adrenaline sooner (median 5.0 vs. 7.0 min, p = 0.022) and required a lower total dose than non-survivors (2.0 vs. 3.0 mg, p < 0.001). For survivors, there was no significant association between the time to first adrenaline dose and favorable neurological outcome as measured by Cerebral Performance Category (CPC). Among survivors, those that received less than 2 mg of adrenaline had a more favorable neurologic outcome than those administered > 3 mg. (CPC 1-2 16.6% vs. 12.5%, p = 0.004).

CONCLUSION: Early adrenaline administration is associated with a higher percentage of survival to discharge but not associated with favorable neurological outcome. Those patients with a favorable neurologic outcome received a lower total adrenaline dose prior to ROSC.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Sigal AP, Sandel KM, Buckler DG, et al. Impact of adrenaline dose and timing on out-of-hospital cardiac arrest survival and neurological outcomes. Resuscitation. 2019. PMID: 30991079. doi:10.1016/j.resuscitation.2019.04.018

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。